Remdesivir First Anti-Viral Medicine To Gain FDA Approval

Photo Credit Gilead

 

On Thursday October 22, 2020 the US FDA approved Gilead Sciences Inc’s anti-viral medicine remdesivir to treat COVID-19 patients including children above the age of 12 and adults, who weigh at least 40 kgs. Although remdesivir had been used as an emergency treatment for the general population including President Trump, the anti-viral drug has now gained FDA approval with a few riders about its use.

 

Remdesivir cannot be used by the general population. It should be used for patients who are admitted in hospital or health care treatment for COVID-19. Velkury is the brand name of remdesivir. Studies have shown that remdesivir is ineffective as a cure for the viral infection but shortens recovery rate by five days when compared with standard treatments. It does so by arresting the multiplication of the virus inside the body once it’s administered.

 

“The FDA is committed to expediting the development and availability of COVID-19 treatments during this unprecedented public health emergency, “ said FDA Commissioner Stephen M Hahn MD. The FDA is an agency within  the US Department of Health and Human Services. It protects the public healthy and safety of its citizens.
Source: www.fda.gov


Follow us on Google news for more updates and News










PLEASE READ THE IMPORTANT DISCLOSURES BELOW.

This content is being provided to you for informational purposes only. The content has been prepared by third parties not affiliated with CWEB Inc, a business. This content and any information contained therein, does not constitute a recommendation by CWEB to buy, sell or hold any security, financial product or instrument referenced in the content. This information neither is, nor should be construed as an offer, or a solicitation of an offer, to buy or sell securities by CWEB Inc. CWEB Inc. does not offer or provide any opinion regarding the nature, potential, value, suitability or profitability of any particular investment or investment strategy, and you shall be fully responsible for any investment decisions you make, and such decisions will be based solely on your evaluation of your financial circumstances, investment objectives, risk tolerance, and liquidity needs.

Unless stated otherwise, the web content provided by the CWEB family of companies is for educational purposes only. The information and tools provided neither are, nor should be construed, as an offer, or a solicitation of an offer, to buy or sell securities by CWEB Inc. or its affiliates. Unless stated otherwise, no information presented constitutes a recommendation by CWEB Inc. or its affiliates to buy, sell or hold any security, financial product or instrument discussed therein or to engage in any specific investment strategy.

Full Disclaimer


>